CEO Amir Nashat, who has decades of experience in biotech at Polaris Partners, describes the work Soufflé has been doing to catalogue often rare targets and design ligands that carry payloads to them such as siRNAs and ASOs. The company plans to be in the clinic next year and is starting out with muscle conditions.
View all episodes
By BiotechTV
5
44 ratings
CEO Amir Nashat, who has decades of experience in biotech at Polaris Partners, describes the work Soufflé has been doing to catalogue often rare targets and design ligands that carry payloads to them such as siRNAs and ASOs. The company plans to be in the clinic next year and is starting out with muscle conditions.
30,626 Listeners
1,863 Listeners
1,085 Listeners
325 Listeners
6,059 Listeners
60 Listeners
9,840 Listeners
86 Listeners
34 Listeners
19 Listeners
260 Listeners
497 Listeners
0 Listeners
4 Listeners
2 Listeners
6 Listeners